Insider Selling: Insmed Incorporated (NASDAQ:INSM) Insider Sells $134,781.36 in Stock

Insmed Incorporated (NASDAQ:INSMGet Rating) insider John Drayton Wise sold 7,154 shares of the firm’s stock in a transaction dated Tuesday, November 22nd. The stock was sold at an average price of $18.84, for a total transaction of $134,781.36. Following the sale, the insider now owns 71,613 shares of the company’s stock, valued at approximately $1,349,188.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Insmed Stock Down 1.9 %

INSM stock opened at $18.37 on Friday. The firm has a 50 day moving average of $20.05 and a 200-day moving average of $21.39. The company has a debt-to-equity ratio of 18.24, a quick ratio of 4.11 and a current ratio of 4.59. Insmed Incorporated has a 12 month low of $16.41 and a 12 month high of $30.72.

Hedge Funds Weigh In On Insmed

A number of large investors have recently modified their holdings of the company. Price T Rowe Associates Inc. MD boosted its position in shares of Insmed by 2.3% in the second quarter. Price T Rowe Associates Inc. MD now owns 16,222,623 shares of the biopharmaceutical company’s stock valued at $319,910,000 after acquiring an additional 364,362 shares during the period. Vanguard Group Inc. lifted its position in Insmed by 0.9% during the third quarter. Vanguard Group Inc. now owns 11,353,970 shares of the biopharmaceutical company’s stock valued at $244,564,000 after purchasing an additional 106,326 shares during the last quarter. Pictet Asset Management SA lifted its position in Insmed by 6.8% during the second quarter. Pictet Asset Management SA now owns 3,797,941 shares of the biopharmaceutical company’s stock valued at $74,895,000 after purchasing an additional 242,092 shares during the last quarter. Bellevue Group AG lifted its position in Insmed by 0.9% during the first quarter. Bellevue Group AG now owns 3,551,776 shares of the biopharmaceutical company’s stock valued at $83,467,000 after purchasing an additional 30,915 shares during the last quarter. Finally, Fairmount Funds Management LLC lifted its position in Insmed by 48.4% during the first quarter. Fairmount Funds Management LLC now owns 1,948,784 shares of the biopharmaceutical company’s stock valued at $45,796,000 after purchasing an additional 635,177 shares during the last quarter.

Analysts Set New Price Targets

INSM has been the subject of several recent research reports. Bank of America initiated coverage on shares of Insmed in a research note on Friday, November 18th. They issued a “buy” rating and a $39.00 target price for the company. StockNews.com initiated coverage on shares of Insmed in a research note on Wednesday, October 12th. They issued a “hold” rating for the company. Cowen reduced their target price on shares of Insmed from $56.00 to $53.00 and set an “outperform” rating for the company in a research note on Friday, October 21st. Credit Suisse Group reduced their target price on shares of Insmed to $52.00 in a research note on Tuesday, November 1st. Finally, Cantor Fitzgerald reduced their target price on shares of Insmed from $53.00 to $49.00 and set an “overweight” rating for the company in a research note on Tuesday, October 25th. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $47.78.

About Insmed

(Get Rating)

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

See Also

Insider Buying and Selling by Quarter for Insmed (NASDAQ:INSM)

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.